---
title: "Kymera Therapeutics CEO Sells 30,000 Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276950826.md"
description: "Kymera Therapeutics' CEO, Nello Mainolfi, sold 30,000 shares of common stock on February 25, 2026, under a Rule 10b5-1 trading plan. The shares were sold at weighted average prices between $89.78 and $93.49, totaling $2,707,812. After the sale, Mainolfi retains ownership of 666,195 shares in the company."
datetime: "2026-02-25T22:30:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276950826.md)
  - [en](https://longbridge.com/en/news/276950826.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276950826.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/276950826.md) | [繁體中文](https://longbridge.com/zh-HK/news/276950826.md)


# Kymera Therapeutics CEO Sells 30,000 Shares

Kymera Therapeutics' Chief Executive Officer, Nello Mainolfi, has sold a total of 30,000 shares of common stock on February 25, 2026, under a Rule 10b5-1 trading plan. The transactions were executed at weighted average prices ranging from $89.78 to $93.49, resulting in a total sale amount of $2,707,812. Following these transactions, Mainolfi directly owns 666,195 shares of Kymera Therapeutics.

Reporter Name

Mainolfi Nello

Relationship

Chief Executive Officer

Type

Sell

Amount

$2,707,812

SEC Filing

Form 4

SEC Filing: Kymera Therapeutics, Inc. \[ KYMR \] - Form 4 - Feb. 25, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [Kymera Therapeutics, Inc. (KYMR.US)](https://longbridge.com/en/quote/KYMR.US.md)

## Related News & Research

- [Kymera Therapeutics (NASDAQ:KYMR) Director Sells $631,738.00 in Stock](https://longbridge.com/en/news/281546235.md)
- [Kymera Therapeutics Updates Bylaws on Federal Securities Litigation](https://longbridge.com/en/news/280850528.md)
- [Kymera Therapeutics Insider Sold Shares Worth $2,707,813, According to a Recent SEC Filing](https://longbridge.com/en/news/276951679.md)
- [Mirum Pharmaceuticals Executives Sell Shares](https://longbridge.com/en/news/279503772.md)
- [WAVE Life Sciences Shares Phase 1 WVE-007 Data Showing Visceral Fat Loss, Muscle Preservation Signal](https://longbridge.com/en/news/280699630.md)